TCR Repertoire Profiling to Predict NSCLC Response to Immunotherapy - Feasibility Study

Watch a 23-minute webinar presentation by Associate Professor Elin Gray, Head of the Melanoma Research Group and Blood-based Cancer Biomarkers Study, exploring the correlation between pre-treatment circulating TCR repertoire metrics and clinical outcomes in advanced non-small cell lung cancer (NSCLC). Learn about a prospective study involving patients treated with first-line pembrolizumab monotherapy and combination chemotherapy, examining how TCR-β repertoire assessment using the Oncomine TCR Beta-SR Assay relates to clinical benefit rate, progression-free survival, overall survival, and immune-related adverse events. Discover key findings including the association between reduced unique clones and improved clinical benefit rates in pembrolizumab-treated patients, as well as the relationships between TCR repertoire diversity metrics and treatment outcomes in combination therapy. Earn PACE credits through Labroots by watching the presentation and completing the certification process, valid until March 2025.